Michael Aldridge Joins Codexis as Senior Vice President, Corporate & Strategic Development
October 17 2016 - 7:00AM
Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company,
announces that Michael Aldridge has joined the company as Senior
Vice President, Corporate & Strategic Development. In
this new position, Mr. Aldridge will manage all aspects of Codexis’
growth initiatives, including leading the expansion of the global
biocatalyst business, striking new CodeEvolver® platform licensing
agreements and building momentum in the Company’s pipeline of
therapeutic drug candidates. He will report to John Nicols,
President and Chief Executive Officer.
“Michael brings to Codexis more than 25 years of experience in
the healthcare and investment banking industries, including more
than a decade as a senior pharmaceutical executive,” said Mr.
Nicols. “I am confident he will step in and create value seamlessly
and rapidly by leveraging his analytical rigor, relevant
biopharmaceutical network and engaging relational approach.
Michael is extremely well qualified to expand Codexis’ strategic
partnerships and lead our business development team globally.”
Commenting on his appointment, Mr. Aldridge said, “I am thrilled
to join Codexis and look forward to working closely with the entire
management team to accelerate Codexis’ strategic successes
leveraging its proven CodeEvolver® protein engineering platform
technology across a host of applications and industries.”
Mr. Aldridge joins Codexis from Sirona Therapeutics Ltd., a
privately held company he founded and served as President and Chief
Executive Officer since 2015. Previously he was Senior Vice
President, Corporate Strategic Development for Questcor
Pharmaceuticals, where he negotiated numerous strategic
transactions that supported a four-fold increase in market
capitalization and the sale of the company to Mallinckrodt
Pharmaceuticals for $5.6 billion. Prior to that, Mr. Aldridge
served as Chief Executive Officer for two drug-development
companies, including privately held Xenome Limited and publicly
traded Peplin, Inc.
Before transitioning to those pharmaceutical industry roles, Mr.
Aldridge held multiple investment banking positions, primarily in
healthcare, at leading international financial firms including
Wilson HTM Investment Group, Bear Stearns and Co., Volpe, Brown,
Whelan and Company and SG Warburg Group.
A native of New Zealand, Mr. Aldridge received a Master of
Applied Finance from Macquarie University in Sydney, Australia and
a BS with honors in Chemistry from the University of Canterbury in
Christchurch, New Zealand.
About CodeEvolver® Protein Engineering Platform
Technology
Codexis’ proprietary CodeEvolver® protein engineering platform
enables the rapid development of custom-designed enzymes that are
highly optimized for a specific function. The CodeEvolver® platform
is comprised of proprietary methods for the optimization of
proteins through the design and generation of diverse genetic
libraries, automated screening techniques, algorithms for the
interpretation of screening data and predictive modelling.
The Codexis CodeEvolver® platform technology is covered by more
than 250 issued patents and pending patent applications
worldwide.
About Codexis, Inc.
Codexis, Inc. is a leading protein engineering company that
applies its technology to the development of biocatalysts for
commercial manufacture of pharmaceuticals and fine chemicals.
Codexis’ proven technology enables implementation of biocatalytic
solutions to meet customer needs for rapid, cost-effective and
sustainable manufacturing. For more information, see
www.codexis.com.
Forward-Looking Statements
This press release contains forward-looking statements relating
to Codexis’ announcement that Michael Aldridge has joined the
company as Senior Vice President, Corporate & Strategic
Development and expresses Codexis’ intention to expand its global
biocatalyst business, enter into new CodeEvolver® platform
licensing agreements and build momentum in its pipeline of
therapeutic drugs. You should not place undue reliance on these
forward-looking statements because they involve known and unknown
risks, uncertainties and other factors that are, in some cases,
beyond Codexis’ control and that could materially affect actual
results. Factors that could materially affect actual results
include Codexis’ dependence on its licensees and collaborators;
Codexis’ dependence on a limited number of products and customers
in its pharmaceutical business; potential adverse effects to
Codexis’ business if its customers’ pharmaceutical products are not
received well in the markets; Codexis’ ability to deploy its
technology platform in new market spaces; Codexis’ dependence on
key personnel; Codexis’ ability to compete may decline if it loses
some of its intellectual property rights; third party claims that
Codexis infringes third party intellectual property rights; and
Codexis could face increased competition if third parties
misappropriate Codexis biocatalysts. Additional factors that could
materially affect actual results can be found in Codexis’ Annual
Report on Form 10-K filed with the Securities and Exchange
Commission on March 8, 2016 and in Codexis’ Quarterly Report on
Form 10-Q filed with the Securities and Exchange Commission on
August 8, 2016, including, in each case, under the caption “Risk
Factors.” Codexis expressly disclaims any intent or obligation to
update these forward-looking statements, except as required by
law.
Codexis Contacts:InvestorsLHAJody Cain,
310-691-7100jcain@lhai.com
MediaThat’s Nice LLCGuy TieneGuy@thatsnice.com
Codexis (NASDAQ:CDXS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Codexis (NASDAQ:CDXS)
Historical Stock Chart
From Apr 2023 to Apr 2024